Antigen binding protein and its use as addressing product for the treatment of cancer
US9689862B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 5, 2012 |
| Grant date | Jun 27, 2017 |
| Priority date | — |
| Expiry date | Nov 5, 2032 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to an antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to an antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.